Cancer Supportive Care Product Market

Cancer Supportive Care Product Market Outlook (2024 to 2034)

The global cancer supportive care product market is projected to increase from a value of US$ 35.47 billion in 2024 to US$ 68.93 billion by the end of 2034. Worldwide sales of cancer-supportive care products are forecasted to rise at a CAGR of 6.9% from 2024 to 2034.

Cancer is widely known for its severity and the significant side effects it can cause. Fortunately, cancer supportive care products help mitigate these side effects, enabling patients to receive necessary treatment more easily. Physicians often recommend starting cancer supportive care medications immediately following a diagnosis. According to the National Cancer Institute, these medications positively impact both mental and physical health.

Evidence shows that supportive care medications play a crucial role in post-therapy treatment for cancer patients. They help patients avoid side effects and alleviate cancer-related complications. Chemotherapy, one of the most effective cancer treatments, can lead to increased toxicity and reduced quality of life over time. Supportive care medications address these side effects, contributing to the expansion of the cancer supportive care product market size.

Most professionals, including therapists, dietitians, pain management specialists, palliative care experts, and medical advisors, deliver supportive cancer care medications or sessions. These medications can improve patient outcomes and quality of life.

• The National Cancer Institute estimates that by the end of 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with 611,720 deaths expected. This high incidence rate drives the demand for cancer supportive care products, as more people seek to mitigate side effects.
• The World Cancer Research Fund International (WCRF) predicts over 24 million new cancer cases by 2035, excluding skin cancer.
• In 2017, the National Cancer Institute (NIH) reported over 1.5 million new cancer cases in the United States.

The rising number of cases will lead to an increased need for chemotherapy and radiation therapy. These therapies often have side effects that cancer-supportive care products help mitigate. All of these factors are contributing to global cancer supportive care product market growth.

Report Attribute	Detail
Cancer Supportive Care Product Market Size (2024E)	US$ 35.47 Billion
Forecasted Market Value (2034F)	US$ 68.93 Billion
Global Market Growth Rate (2024 to 2034)	6.9% CAGR
Canada Market Growth Rate (2024 to 2034)	7.5% CAGR
China Market Value (2034F)	US$ 6.08 Billion
North America Market Share (2024E)	37.7%
East Asia Market Share (2034F)	20.4%
Key Companies Profiled	Amgen Inc.; Baxter International Inc.; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc (GSK) (Tesaro); Helsinn Healthcare; Heron Therapeutics; Johnson & Johnson (Janssen Global Services, LLC); Merck KGAA; Novartis International AG (Sandoz); Bristol Myers Squibb Company; Eli Lilly and Company; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; AbbVie Inc.; AstraZeneca PLC; Bayer AG; GlaxoSmithKline Plc.

What’s Increasing the Profitability of Cancer Care Product Suppliers?

“Rising Prevalence of Cancer Necessitating Chemotherapy and Leading to Severe Side Effects”

Globally, chemotherapy is the most commonly used cancer treatment. Traditional chemotherapy aims to eradicate cancer cells but often causes severe side effects such as anemia, mouth sores, nausea, vomiting, hair loss, and skin infections, which can be short-term or long-lasting. Supportive care medications for cancer patients significantly mitigate these harmful effects by protecting healthy cells and organs from the impact of cancer cells before they occur.

Cancer supportive care drugs reduce treatment side effects and enhance tolerance to aggressive therapies.

• In August 2021, the Centers for Medicare and Medicaid Innovation (CMMI) reported that patients using supportive care medications experienced fewer emergency room visits, hospital stays, and department visits.

With growing awareness of chemotherapy's adverse effects, the benefits of supportive cancer care medications are expected to drive market growth.

“Focus of Several Governments on Improving Cancer Awareness”

Governments worldwide are focusing on improving the oncology sector's overall infrastructure to provide cancer patients with high-quality healthcare services, driven by growing public health concerns. This is a key cancer supportive care product market trend. Investments in new cancer treatment centers and centralized procurement schemes are being made by various governments globally. For instance, England's 10-year long-term cancer strategy aims to significantly increase patient survival rates by 2028.

The Indian government is striving to increase the number of linear accelerators necessary for radiation therapy. This heightened governmental attention and investment in the oncology sector offer researchers numerous opportunities to develop innovative and advanced supportive care medications for cancer patients.

• The World Health Organization reports that significant new legislative, programmatic, and financial commitments, including nearly US$ 600 million in additional funding, were announced by governments, donors, multilateral organizations, and partners to eradicate cervical cancer.

What is Limiting the Market from Reaching its Full Potential?

“High Expenditure and Restriction on Opioid Pain Killer Use”

Cancer patients frequently use opioid medications to manage severe pain. Doctors often prescribe opioids to patients undergoing chemotherapy or other treatments for their supportive care benefits. However, due to their severe side effects–such as depression, osteoporosis, respiratory issues, development of other serious conditions, neurological consequences, and permanent brain damage–opioids are now less commonly prescribed.

Opioids can also lead to coma or death. Long-term use of opioids may result in infertility in women and erectile dysfunction in men, according to various clinical studies. In response to this ongoing public health crisis, numerous governments and health ministries are implementing stringent laws and regulations to limit or ban the prescription of opioids. These strict regulations on painkillers are likely to impede the growth of the cancer-supportive care product market.

Country-wise Insights

Cancer supportive care products are becoming popular in various countries including the United States, China, Canada, Japan, and South Korea. The markets in East Asia and North America are projected to expand at a CAGR of 7% from 2024 to 2034.

What is Leading to Significant Market Growth in Mexico?

“Government Initiatives Enhancing Access to Cancer Care”

Attribute	Mexico
Market Value (2024E)	US$ 636 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 1.35 Billion

The market for supportive care products in Mexico is expanding at a significant rate as a result of government programs targeted at enhancing access to cancer treatment and care. The use of supportive care products by healthcare practitioners may be encouraged or subsidized by these programs.

• Third-generation Mexican Americans have a 66% higher risk of liver cancer than first-generation Mexican Americans, according to research headed by the USC Keck School of Medicine. The 2023 study examined the disease's risk factor across over 30,000 Mexican Americans.

How are Market Players in China Able to Improve Their Profit margins?

“Regulatory Support and Guidelines Added with Patient-Centric Approach”

Attribute	China
Market Value (2024E)	US$ 2.73 Billion
Growth Rate (2024 to 2034)	8.3% CAGR
Projected Value (2034F)	US$ 6.08 Billion

The importance of supportive care in cancer therapy has been highlighted in guidelines and procedures established by regulatory bodies and healthcare organizations. Adherence to these principles is driving the adoption of supportive care medications and their integration into routine cancer care regimens.

Category-wise Evaluation

Based on distribution channels, hospital pharmacies are poised to occupy a 74.6% cancer supportive care product market share in 2024.

What Primary Benefit Do Erythropoietin-Stimulating Agents (ESAs) Provide to Cancer Patients?

“ESAs Improving Oxygen Delivery to Tissues and Organs”

Attribute	Erythropoietin Stimulating Agents
Segment Value (2024E)	US$ 8.76 Billion
Growth Rate (2024 to 2034)	7% CAGR
Projected Value (2034F)	US$ 17.23 Billion

Erythropoietin-stimulating agents (ESAs) are pharmaceuticals that promote the production of red blood cells in the body. One of the primary benefits of ESAs is their ability to treat anemia, particularly in cancer patients undergoing chemotherapy or those with chronic kidney disease. By boosting red blood cell production, ESAs enhance oxygen delivery to tissues and organs, thereby reducing feelings of weakness and fatigue.

Why are Supportive Care Products Extensively Used in Lung Cancer Treatment?

“Severity and Symptom Burden Associated with Lung Cancer”

Attribute	Lung Cancer
Segment Value (2024E)	US$ 5.21 Billion
Growth Rate (2024 to 2034)	7% CAGR
Projected Value (2034F)	US$ 10.22 Billion

Among cancer patients undergoing therapy, lung cancer stands out as a critical indication for supportive care products. The specific needs of lung cancer patients drive the demand for specialized supportive care to manage symptoms and improve quality of life. Meeting these particular demands is essential to providing comprehensive care for lung cancer patients.

Business Rivalry

Key players in the cancer supportive care product industry are adapting themselves to key market trends such as monoclonal antibodies and cancer immunotherapy.

• The clinical-stage biotechnology company First Light Acquisition Group and Calidi Biotherapeutics, Inc., announced their merger in 2023. Their goal is to develop oncolytic virotherapy using a stem cell-based delivery system for cancer treatments.
• In December 2022, the FDA approved atezolizumab (Tecentriq), an immunotherapy drug, for treating Alveolar Soft Part Sarcoma (ASPS) in adults and children aged 2 and older if the disease has metastasized or is inoperable.
• Novartis received FDA approval in 2022 to use Pluvicto for treating adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously undergone chemotherapy with taxanes and androgen receptor pathway inhibitors.
• Gilead and Dragonfly announced their collaboration on natural killer cell engagers in cancer starting in 2022. As part of the agreement, Gilead acquired a global license from Dragonfly for their immunotherapy development DF7001, which targets 5T4.

Fact.MR provides detailed information about the price points of key cancer supportive care product manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Key Segments of Cancer Supportive Care Product Market Research

• By Drug Class :

  • Anti-Emetics
  • Anti-Infective
  • Bisphosphonates
  • Erythropoietin Stimulating Agents
  • Granulocyte Colony Stimulating Factor
  • Monoclonal Antibodies
  • Nonsteroidal Anti-Inflammatory Drugs
  • Opioid Analgesics

• By Indication :

  • Bladder Cancer
  • Breast Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Ovary Cancer
  • Prostate Cancer
  • Others

• By Distribution Channel :

  • Compounding Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa